Novo Nordisk A/S (NVO)vsNovartis AG ADR (NVS)
NVO
Novo Nordisk A/S
$43.24
+0.12%
HEALTHCARE · Cap: $205.92B
NVS
Novartis AG ADR
$140.92
-0.39%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 481% more annual revenue ($329.43B vs $56.69B). NVO leads profitability with a 35.3% profit margin vs 22.5%. NVS appears more attractively valued with a PEG of 3.22. NVO earns a higher WallStSmart Score of 58/100 (C).
NVO
Buy58
out of 100
Grade: C
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NVO.
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$140.92
$47.63 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Attractively priced relative to earnings
Every $100 of equity generates 53 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 42.5%
Generating 42.4B in free cash flow
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
2.1% revenue growth
Weak financial health signals
Expensive relative to growth rate
Earnings declined 20.6%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on Market Cap, P/E Ratio, Return on Equity. Profitability is solid with margins at 35.3% and operating margin at 42.5%.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : NVO
The primary concerns for NVO are Revenue Growth, Piotroski F-Score, PEG Ratio.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
NVO is growing revenue faster at 2.1% — sustainability is the question.
NVO generates stronger free cash flow (42.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVO scores higher overall (58/100 vs 51/100), backed by strong 35.3% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?